These guidelines are a multidisciplinary collaboration to provide recommendations for clinical practice and define best practice by using up-to-date available evidence alongside the expert, consensus opinion of cancer care professionals for the safe delivery of cancer therapy. They aim to prevent medication errors and patient harm by standardising the complex process of providing medications for the treatment of cancer.
The guidelines should be seen as point of reference for practitioners providing medications for the treatment of cancer and can be used as a framework to aid best practice within the multidisciplinary team. They should serve as a unifying platform that ensures seamless integration of processes, facilitates understanding of shared responsibility while setting standards to provide safe and effective treatment for cancer patients.
Guideline developer:
Clinical Oncology Society of Australia
COSA guidelines for the safe prescribing, dispensing and administration of systemic anti-cancer therapy
These guidelines have been updated and are open for consultation from 3 September 2026 to 30 September 2026.
Please visit https://www.cosa.org.au/COSA/Guidelines/Cancer-Therapy-Medication-Safety-Guidelines.aspx to review and provide feedback.
*Note: If you experience difficulty accessing this guideline please contact us on cosa@cancer.org.au